Zacks Investment Research downgraded shares of China Biologic Products, Inc. (NASDAQ:CBPO) from a hold rating to a sell rating in a research report report published on Monday morning.

According to Zacks, “China Biologic Products, Inc., through its indirect majority-owned subsidiary, is principally engaged in the research, development, production, manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Its subsidiary, Shandong Taibang Biological Products Co. Ltd., operates from its manufacturing facility located in Taian City, Shandong Province. The Company’s principal products include its approved human albumin and immunoglobulin products. These human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases. “

Other research analysts have also issued research reports about the stock. Goldman Sachs Group, Inc. (The) began coverage on shares of China Biologic Products in a research report on Tuesday, May 30th. They set a neutral rating for the company. BidaskClub lowered shares of China Biologic Products from a sell rating to a strong sell rating in a research report on Saturday. Finally, Jefferies Group LLC reissued a buy rating on shares of China Biologic Products in a research report on Friday. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company. China Biologic Products presently has a consensus rating of Hold and a consensus price target of $132.00.

Shares of China Biologic Products (CBPO) traded down 1.655% during mid-day trading on Monday, hitting $94.195. The stock had a trading volume of 143,599 shares. The stock has a 50-day moving average price of $105.95 and a 200 day moving average price of $108.22. The stock has a market cap of $2.57 billion, a P/E ratio of 24.517 and a beta of 1.70. China Biologic Products has a 52 week low of $94.00 and a 52 week high of $137.39.

China Biologic Products (NASDAQ:CBPO) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.30 by $0.05. The firm had revenue of $89.28 million during the quarter, compared to analyst estimates of $97.33 million. China Biologic Products had a net margin of 31.55% and a return on equity of 21.86%. The business’s revenue was down 2.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.26 EPS. On average, equities analysts forecast that China Biologic Products will post $4.99 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/08/08/china-biologic-products-inc-nasdaqcbpo-downgraded-to-sell-at-zacks-investment-research.html.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Jennison Associates LLC increased its position in China Biologic Products by 0.8% in the second quarter. Jennison Associates LLC now owns 5,775 shares of the biopharmaceutical company’s stock valued at $653,000 after buying an additional 44 shares during the last quarter. BARING ASSET MANAGEMENT Ltd increased its position in China Biologic Products by 43.4% in the second quarter. BARING ASSET MANAGEMENT Ltd now owns 166,774 shares of the biopharmaceutical company’s stock valued at $18,862,000 after buying an additional 50,465 shares during the last quarter. Comerica Bank increased its position in China Biologic Products by 66.3% in the second quarter. Comerica Bank now owns 22,805 shares of the biopharmaceutical company’s stock valued at $2,344,000 after buying an additional 9,095 shares during the last quarter. Bank of New York Mellon Corp increased its position in China Biologic Products by 4.1% in the second quarter. Bank of New York Mellon Corp now owns 586,459 shares of the biopharmaceutical company’s stock valued at $66,328,000 after buying an additional 22,932 shares during the last quarter. Finally, SG Americas Securities LLC increased its position in China Biologic Products by 30.1% in the second quarter. SG Americas Securities LLC now owns 17,414 shares of the biopharmaceutical company’s stock valued at $1,970,000 after buying an additional 4,028 shares during the last quarter. Institutional investors own 74.09% of the company’s stock.

China Biologic Products Company Profile

China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment.

Get a free copy of the Zacks research report on China Biologic Products (CBPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related stocks with our FREE daily email newsletter.